Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1 to 5, 2023.
Details on Fulgent’s poster presentations at SITC are as follows:
Title: Critical clinical evaluation of plasma to tumor tissue concordance by cancer type using Illumina’s cell-free ctTSO500 commercial liquid biopsy assay
Date and Time: Saturday, November 4 from 9:00 a.m. to 8:30 p.m. PDT
Abstract/Poster #: 222-B
Title: FID-007: Nanoencapsulated Paclitaxel Derived from a Novel Nano-Drug Delivery Platform
Date and Time: Saturday, November 4 from 9:00 a.m. to 8:30 p.m. PDT
Abstract/Poster #: 782-B
The posters will be available following the presentations on the Investor Relations section of the company’s website at https://ir.fulgentgenetics.com/presentations.
About FID-007
FID-007 consists of paclitaxel encapsulated in a polyethyloxazoline (PEOX) polymer excipient designed to enhance PK, biodistribution, and tolerability. In addition to allowing the drug to remain in solution until it can enter a cancer cell, the PEOX nanoparticle is designed to preferentially deliver paclitaxel to the tumor through the leaky hyperpermeable vasculature.
Lesen Sie auch
About Fulgent Pharma
Fulgent Pharma has developed and possesses a novel nanoencapsulation technology, which includes over 40 patents and a targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of both new and existing cancer drugs. Fulgent Pharma began as Fulgent Therapeutics in Temple City, California, in June 2011. As the company progressed into the sphere of personalized medicine, it also started delving into clinical genetic testing – a natural complement. In 2016, Fulgent Therapeutics split into two separate entities – Fulgent Pharma and Fulgent Genetics – in order to better pursue their independent objectives. Today, Fulgent Pharma is fully focused on perfecting drug candidates for treating a broad range of cancers. Its partners in this endeavor include the University of Southern California, Moffitt Cancer Center, and ANP Technologies.